CC
ACAD icon

Cipher Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Cipher Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$479K Sell
25,932
-19,457
-43% -$482K 0.22% 161
2023
Q4 		$1.42M Buy
45,389
+25,033
+123% +$598K 0.46% 47
2023
Q3 		$424K Buy
+20,356
New +$553K 0.3% 115

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cipher Capital's ACAD Position: Q1 2024 in Review

Cipher Capital reduced its Acadia Pharmaceuticals (ACAD) stake by 43% in Q1 2024, selling an estimated $482K and leaving 25,932 shares worth $479K. The position accounts for 0.22% of the portfolio, ranked #161.

Cipher Capital first reported a position in ACAD in Q3 2023 and has held it in 3 quarters since. The position peaked at $1.42M in Q4 2023. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Cipher Capital held 25,932 shares of Acadia Pharmaceuticals worth $479K as of Q1 2024.
  • Cipher Capital sold 19,457 Acadia Pharmaceuticals shares in Q1 2024, an estimated $482K.
  • Acadia Pharmaceuticals made up 0.22% of Cipher Capital's portfolio in Q1 2024, its #161 holding.
  • Cipher Capital first reported a position in Acadia Pharmaceuticals in Q3 2023 and has held it in 3 quarters since.
  • Cipher Capital's Acadia Pharmaceuticals position peaked at $1.42M in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.